A Randomized Controlled Trial to Evaluate the Efficacy of Acupuncture Versus Aromatherapy as Treatments to Lessen Nausea, Vomiting and Anxiety Associated With Adriamycin and Cytoxan
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04116697 |
Recruitment Status :
Recruiting
First Posted : October 7, 2019
Last Update Posted : February 7, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Nausea Vomiting Anxiety | Other: Acupuncture Other: Aromatherapy | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 60 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Supportive Care |
Official Title: | A Randomized Controlled Trial to Evaluate the Efficacy of Acupuncture Versus Aromatherapy as Treatments to Lessen Nausea, Vomiting and Anxiety Associated With Adriamycin and Cytoxan |
Actual Study Start Date : | October 23, 2019 |
Estimated Primary Completion Date : | March 2021 |
Estimated Study Completion Date : | March 2021 |

Arm | Intervention/treatment |
---|---|
Experimental: Acupuncture with Anti-Emetics |
Other: Acupuncture
Acupuncture is a form of alternative medicine in which thin needles are inserted into the body. |
Experimental: Aromatherapy with Anti-Emetics |
Other: Aromatherapy
Aromatherapy is a form of alternative medicine in which you will inhale aromatic plant extracts and essential oils. |
No Intervention: Control Group |
- Improvement in Nausea [ Time Frame: 45 days ]Patients will complete an Edmonton Symptom Assessment Scale. Patients will rate their level of nausea from 0-10 with 10 being the worst possible nausea. Patients will also complete a symptom diary where they will track their level of nausea and how often they are nauseous. Patients will also complete an Anti-Emetic Diary which will track how often they are taking their anti-emetic medications to combat nausea.
- improvement in anxiety [ Time Frame: 45 days ]Patients will complete an Edmonton Symptom Assessment Scale. Patients will rate their level of anxiety from 0-10 with 10 being the worst possible anxiety. Patients will also complete a symptom diary where they will track their level of anxiety and how often they are anxious.
- improvement in vomiting [ Time Frame: 45 days ]Patients will complete a symptom diary where they will track how often they vomit. Patients will also complete an Anti-Emetic Diary which will track how often they are taking their anti-emetic medications to combat vomiting.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
i) Inclusion
- At least 18 years of age on the day of signing informed consent
- Patient has a diagnosis of breast cancer
- Patient is planned to start Adriamycin and Cytoxan chemotherapy
ii) Exclusion
- Patients who are unable to adhere to the protocol or treatment schedule
- Patients who have a concurrent illness or take medication that induces nausea independent of chemotherapy
- Patients undergoing radiotherapy or hormone therapy during chemotherapy treatments
- Patients who have a sensitive and/or poor sense of smell
- Patients who are allergic to essential oils, specifically peppermint, ginger, and/or lavender
- Patients who are already using essential oils or acupuncture for symptom management and are unwilling to stop while participating in this study
- Patients who are afraid of or unwilling to receive acupuncture stimulation
- Patients who are allergic to stainless steel needles
- Thrombocytopenia (Platelets < 20,000)
- Patients who have received aromatherapy and/or acupuncture treatment within 1 week of starting treatment on this study

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04116697
Contact: Jamie Ketas | 201-894-3418 | Jamie.Ketas@EHMCHealth.org |
United States, New Jersey | |
Englewood Health | Recruiting |
Englewood, New Jersey, United States, 07631 | |
Contact: Jamie Ketas 201-894-3418 Jamie.Ketas@EHMCHealth.org |
Responsible Party: | Englewood Hospital and Medical Center |
ClinicalTrials.gov Identifier: | NCT04116697 |
Other Study ID Numbers: |
E-19-773 |
First Posted: | October 7, 2019 Key Record Dates |
Last Update Posted: | February 7, 2020 |
Last Verified: | February 2020 |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Nausea Vomiting Anxiety Disorders Mental Disorders Signs and Symptoms, Digestive |